LAT1 inhibition has been associated with reduced cellular proliferation, often associated with reduced phosphorylation level of mTOR and its downstream effectors in several cancer models, including lung [52,95], colorectal [43] and breast cancer [96]. Here, SLC7A5 is linked to breast cancer.